IT - EN
Pharmaceutical Operations

Pharmaceutical OperationsR & DPipeline

NAME ORIGINATOR INDICATION DEVELOPMENT STATUS
ISTURISA® Novartis Endogenous Cushing's syndrome/
Cushing's disease                                               
Approved in the USA,
Europe and Switzerland
Filed in Japan and 
other countries
CYSTADROPS® Recordati  Corneal cysteine crystal deposits in patients with cystinosis Approved in the EU and USA
Development of new 
formulations in EU and in USA
REAGILA® Gedeon Richter Schizophrenia Pediatric post-approval development plan
Methadone   Treatment of cancer-related pain in cases of resistance or intolerance to other opioids Approved in France
CARBAGLU® (Recordati Rare
Diseases)
Hyperammonaemia due to NAGS deficiency and to the main organic acidemias Approved in Canada and the USA for the treatment of organic acidemias
ARS-1 ARS Pharmaceuticals Emergency treatment of severe allergic reactions, including anaphylaxis Filed in EU and pediatric
development plan in progress
REC 0559 Recordati/Mime Tech Neurotrophic keratitis Phase 2 in progress
REC 0545 Recordati/AP-HP Acute decompensation episodes in MSUD Formulation development and
retrospective study in France and Germany